Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 13/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148572 | 0.91 | AKR1C3 (0.43) | MCHR1KCNH2HDAC4MAP4K1HRH3 | |
| SCHEMBL4143084 | 0.86 | KCNH2 (0.47) | MCHR1KCNH2HTR2CMAP4K1HTR1A | |
| SCHEMBL4136377 | 0.79 | HRH3 (0.52) | MCHR1HRH3PDK2 | |
| SCHEMBL4136371 | 0.79 | HRH3 (0.52) | MCHR1HRH3PDK2 | |
| SCHEMBL4136716 | 0.76 | HDAC4 (0.38) | HDAC4 | |
| SCHEMBL4136657 | 0.76 | HRH3 (0.48) | MCHR1KCNH2HTR2CHTR1AHRH3 | |
| SCHEMBL4142089 | 0.75 | HRH3 (0.42) | MCHR1MAP4K1HRH3PDK2FAAH | |
| SCHEMBL4147507 | 0.74 | MCHR1 (0.41) | MCHR1KCNH2HDAC4HTR2CHTR1A | |
| SCHEMBL4136231 | 0.74 | HRH3 (0.45) | MCHR1HRH3PDK2 | |
| SCHEMBL4139503 | 0.74 | MEN1 (0.44) | HTR1AHRH3FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | MCHR1 287/4885KCNH2 657/4885HDAC4 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.